Table 4.
Annual national consumption of systemic antifungal compounds in Iceland, 2000 to 2011, expressed as defined daily doses per 1,000 inhabitants
| Yr | DDD per 1,000 inhabitantsa |
|||||
|---|---|---|---|---|---|---|
| AMB | FLC | ITC | VRC | PSC | ECD | |
| 2000 | 3.2 | 39.5 | 94.8 | |||
| 2001 | 1.4 | 42.9 | 28.1 | |||
| 2002 | 5.6 | 37.7 | 24.1 | 0.10 | ||
| 2003 | 2.7 | 42.0 | 22.9 | 0.86 | 0.06 | |
| 2004 | 0.1 | 48.8 | 25.2 | 0.24 | 0.14 | |
| 2005 | 1.1 | 59.0 | 29.3 | 0.54 | 0.06 | |
| 2006 | 4.4 | 64.1 | 26.4 | 0.47 | 0.18 | |
| 2007 | 5.3 | 68.9 | 25.2 | 0.75 | 0.01 | 0.23 |
| 2008 | 1.4 | 73.2 | 25.9 | 1.72 | 0.02 | 0.30 |
| 2009 | 4.7 | 79.0 | 19.2 | 0.76 | 0.16 | 0.11 |
| 2010 | 2.6 | 78.7 | 16.3 | 3.76 | 0.01 | 0.31 |
| 2011 | 1.7 | 95.1 | 16.0 | 2.49 | 0.05 | 0.32 |
a
AMB, amphotericin B; FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; PSC, posaconazole; ECD, echinocandins.